Research
Cellular
Fibrinolytic dysfunction, indicated by elevated plasminogen activator inhibitor-1 levels, mediates the increased risk of CVD in individuals with metabolic syndrome.
Interventions aimed at improving fibrinolytic function may be beneficial for individuals with metabolic syndrome.
StrongSupportsmedium confidence
This difference in CVD prevalence among the groups was attenuated after adjustment for plasminogen activator inhibitor-1 levels, suggesting that fibrinolytic dysfunction mediates the increased risk of CVD in individuals with the metabolic syndrome.
Why this rating
Based on the large sample size of 1276 adults.
Source
Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease
Sonia S. Anand et al. · Circulation · 2003
DOI 10.1161/01.cir.0000080884.27358.49
cross-sectional · n=1276Cited 290×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The prevalence of metabolic syndrome was 25.8% overall, varying by ethnic group: 41.6% among Native Indians, 25.9% among South Asians, 22.0% among Europeans, and 11.0% among Chinese.Strong
- Individuals with metabolic syndrome had a higher prevalence of cardiovascular disease (CVD) at 17.2% compared to 7.0% in those without it.Strong
Related findings · Cellular
- Athletes aiming to reduce fat mass and preserve FFM should consume protein intakes in the range of ∼1.8-2.7 g kg(-1) d(-1).Strong
- A minimum daily protein intake of ≥1.6 g/kg is necessary to observe significant improvements in muscle mass from whey protein supplementation.Strong
- Most athletes ideally need 1.2 to 2.0 grams/kg of body weight/day of protein, preferably split across 3-4 meals.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →